About Versanis Bio
Versanis Bio is a company based in Oakland (United States) founded in 2020 was acquired by Lilly in July 2023. Versanis Bio has raised $70 million across 1 funding round from investors including Lilly, Atlas Venture and Medicxi. Versanis Bio operates in a competitive market with competitors including Adocia, Altimmune, Carmot, BioAge Labs and Fractyl, among others.
- Headquarter Oakland, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Versanis Bio, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Versanis Bio
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Versanis Bio
Versanis Bio has successfully raised a total of $70M through 1 strategic funding round. The most recent funding activity was a Series A round of $70 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Versanis Bio
Versanis Bio has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, Atlas Venture and Medicxi.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life science and biotechnology sectors
|
Locked | Locked | Locked | |
|
Early-stage life science focused VC firm investing in geographies such as Europe and the US
|
Locked | Locked | Locked | |
|
Traditional pharmaceutical medicines are developed for multiple health fields.
|
Locked | Locked | Locked |
Investor details for Versanis Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Versanis Bio
Investment portfolio details for Versanis Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Versanis Bio
Detailed financials for Versanis Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Versanis Bio Comparisons
Peer comparison for Versanis Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Versanis Bio
Versanis Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adocia, Altimmune, Carmot, BioAge Labs and Fractyl, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| Locked | Locked | Locked |
Disease-modifying therapies for metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Bioinformatics platform is provided for biomarkers and drug discovery.
|
|
| Locked | Locked | Locked |
Endoscopic procedures for type-2 diabetes treatment are developed.
|
|
| Locked | Locked | Locked |
Peptide-based therapies for obesity and cardiometabolic disorders are developed.
|
Detailed competitors of Versanis Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Versanis Bio
Complete news archive for Versanis Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Versanis Bio
Versanis Bio was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Versanis Bio is headquartered in Oakland, United States. It is registered at Oakland, California, United States.
Lloyd Klickstein is the current CEO of Versanis Bio.
Versanis Bio is a funded company, having raised a total of $70M across 1 funding round to date.
Versanis Bio was founded in 2020 in Oakland, United States, within the biotechnology sector. Focus is placed on developing treatments for obesity and related metabolic conditions. The primary drug candidate, bimagrumab, functions as an activin receptor type II antagonist to enhance muscle mass while decreasing fat. Operations center on advancing this therapy through clinical stages for patient applications in obesity management.
Versanis Bio's top competitors include Adocia, BioAge Labs and Fractyl.
Versanis Bio has 3 investors. Key investors include Lilly, Atlas Venture, and Medicxi.